Published on : May 16, 2017
Albany, New York, May 16, 2017: A new study focusing on a rare genetic condition, which is known as ‘Hereditary Angioedema’ has been added to the massive repository of Market Research Hub (MRH), and titled as “Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)”. The report identifies the key trends shaping and driving the global Hereditary Angioedema market. The report also provides insights into the competitive scenario and the key players are expected to significantly alter the market positioning among the market leaders. The growth of overall global hereditary angioedema market has also been forecasted for the years 2017-2021. Geographically, the research includes a detailed regional analysis of the US and Europe hereditary angioedema market comprising of the hereditary market by value, segments and growth.
As per the key highlights, the global hereditary angioedema market is projected to increase at a healthy rate during the forecasted period (2017-2021). There are several growth factors analyzed in the study that are driving the market. Currently, advantages of preventive therapy, approval of Berinert for pediatric treatment, launch of Haegarda C1 inhibitor and some other major products in the pipeline are the major growth drivers. Moreover, the report also assesses the key opportunities in the market and summaries the factors that are and will be driving the growth of the industry.
The report firstly introduces Angioedema, its types, Hereditary Angioedema, C1 inhibitor Overview. Angioedema can be defined as a disorder in which there is a rapid inflammation of the dermis, mucosa, sub mucosal tissues and subcutaneous tissue. Hereditary Angioedema is a type of rapid inflammation and is a very rare and possibly life-threatening genetic condition. It most commonly affects limbs, face, intestinal and respiratory tract and causes severe swelling in these parts of the body; mainly caused due to genetic mutation. Hereditary angioedema (HAE) classified into three types: Type I HAE, Type II HAE and Type III HAE.
For the treatment of hereditary angioedema, presently there are no drugs available; hence, the medicines that are prescribed to patients help in management of the disease symptoms. It has been analyzed by the study that there have been big improvements in therapies and scientists continue to look for new solutions. C1-inhibitors (including Cinryze, Berinert and ruconest) are considered as the best treatment method for hereditary angioedema. The report highlights products analysis by covering market segments such as Cinryze, Haegarda/Berinert, Acute Therapies (HAE), SHP643 and BX7353.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1066782
Moreover, through the regional analysis, the report examines that increased diagnosis in the US and Europe are one of the prime factors behind the market growth. Oral therapy for hereditary angioedema attacks and SHP643 monoclonal antibody are some of the trends in the global hereditary angioedema market. However, the market also faces certain challenges such as side effects of Cinryze, high prophylaxis cost and long term prophylactic treatment.
Some of the key players operating in the global hereditary angioedema market are as follows:
- Pharming Group NV
- CSL Limited
- Shire Plc
- iBio, Inc.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-866-997-4948US Toll Free
Email : firstname.lastname@example.org